Article: Biogen, Celltech To Collaborate On Crohn's Disease Product.

Article: Results released from CDP 571 phase III ...
Drug Week;  September 13, 2002 ;     700+ words ... ... announced outline results from a phase III study undertaken to evaluate CDP 571 as a new treatment for active ... disease, and also from a further phase III study in steroid-dependent ... assessed the efficacy and safety of CDP 571 in achieving acute clinical ...

Article: CDP 870 phase III milestone payment received ...
Biotech Week;  January 1, 2003 ;     587 words ... ... the initiation of phase III clinical development with CDP 870 in rheumatoid ... initiated a large phase III clinical development program with CDP 870 as a treatment ... finalizing plans for phase III clinical development of CDP 870 as a treatment ...

Article: Celltech Announces Receipt of CDP 870 Phase ...
PR Newswire;  November 26, 2002 ;     700+ words ... ... the initiation of Phase III clinical development with CDP 870 in rheumatoid ... initiated a large Phase III clinical development programme with CDP 870 as a treatment ... finalising plans for Phase III clinical development of CDP 870 as a treatment ...

Article: Companies announce collaboration to develop, commercialize ...
Biotech Week;  May 29, 2002 ;     700+ words ... ... and commercialization of CDP 571, Celltech's humanized ... product, which is in phase III development as a treatment ... inflammatory disorders. CDP 571 is currently being ... two large international phase III studies in Crohn disease ... 2002. In the U.S., CDP 571 has Orphan Drug ...

Article: Biogen and Celltech suffer setback with CDP 571. (Markets: ...
Chemical Market Reporter;  August 5, 2002 ;     700+ words ... ... Celltech Group PLC report two Phase III studies of CDP 571, their humanized anti ... TNF alpha antibody fragment CDP 870, due to begin Phase III trials for Chrohn's disease ... end of 2002, and given that CDP 870's gross margin is above ...

Article: CDP-choline liposomes provide significant reduction in ...
Alternative Medicine Review;  December 1, 2005 ;     690 words ... ... Cytidine-5'-diphosphocholine (CDP-choline, Citicoline, Somazina ... Europe and Japan, while USA phase III stroke clinical trials (oral ... disappointing. Others showed that CDP-choline liposomes significantly ... by suppressing phagocytosis. CDP-choline liposomes deliver ...

Article: CDP 571 didn't meet primary endpoints in study.
Biotech Week;  September 11, 2002 ;     487 words ... ... announced that two phase III studies of CDP 571 did not meet the ... additional analysis of the phase III data and discussions ... authorities. The agreement on CDP 571 between Biogen and ... the results of these phase III studies. This article ...